These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 22360400

  • 1. Successful resolution of inflammation and increased regulatory T cells in sirolimus-treated post-transplant allograft hepatitis.
    Ekong UD, Mathew J, Melin-Aldana H, Wang D, Alonso EM.
    Pediatr Transplant; 2012 Mar; 16(2):165-75. PubMed ID: 22360400
    [Abstract] [Full Text] [Related]

  • 2. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
    Niemczyk M, Zegarska J, Pawłowska M, Wyzgał J, Ciszek M, Paczek L.
    Transpl Immunol; 2009 Jan; 20(3):139-42. PubMed ID: 18834941
    [Abstract] [Full Text] [Related]

  • 3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 4. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, López-Hoyos M, Arias M.
    Transplantation; 2006 Aug 27; 82(4):550-7. PubMed ID: 16926600
    [Abstract] [Full Text] [Related]

  • 5. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 6. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
    Casas-Melley AT, Falkenstein KP, Flynn LM, Ziegler VL, Dunn SP.
    Pediatr Transplant; 2004 Aug 20; 8(4):362-6. PubMed ID: 15265163
    [Abstract] [Full Text] [Related]

  • 7. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation.
    Li Y, Shi Y, Huang Z, Bai Y, Niu Q, Cai B, Wang L, Feng W.
    Int Immunopharmacol; 2011 Dec 20; 11(12):2033-8. PubMed ID: 21911083
    [Abstract] [Full Text] [Related]

  • 8. Peripheral CD4+ CD25+ Treg cell expansion in lung transplant recipients is not affected by calcineurin inhibitors.
    Meloni F, Morosini M, Solari N, Bini F, Vitulo P, Arbustini E, Pellegrini C, Fietta AM.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2002-10. PubMed ID: 17161354
    [Abstract] [Full Text] [Related]

  • 9. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 20; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 10. Combined therapy of CD4(+)CD25(+) regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice.
    Ma A, Qi S, Wang Z, Massicotte E, Dupuis M, Daloze P, Chen H.
    Int Immunopharmacol; 2009 May 20; 9(5):553-63. PubMed ID: 19539558
    [Abstract] [Full Text] [Related]

  • 11. The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation.
    Korczak-Kowalska G, Wierzbicki P, Bocian K, Klosowska D, Niemczyk M, Wyzgal J, Korecka A, Durlik M, Chmura A, Paczek L, Górski A.
    Transplant Proc; 2007 Nov 20; 39(9):2721-3. PubMed ID: 18021968
    [Abstract] [Full Text] [Related]

  • 12. Rapamycin and tacrolimus differentially modulate acute graft-versus-host disease in rats after liver transplantation.
    Xu G, Wang L, Chen W, Xue F, Bai X, Liang L, Shen X, Zhang M, Xia D, Liang T.
    Liver Transpl; 2010 Mar 20; 16(3):357-63. PubMed ID: 20209637
    [Abstract] [Full Text] [Related]

  • 13. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.
    Clin Transplant; 2007 Mar 20; 21(4):460-5. PubMed ID: 17645704
    [Abstract] [Full Text] [Related]

  • 14. Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients.
    Gong N, Chen Z, Wang J, Fang A, Li Y, Xiang Y, Ming C, Zhang W.
    Cell Immunol; 2015 Oct 20; 297(2):87-93. PubMed ID: 26205091
    [Abstract] [Full Text] [Related]

  • 15. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ, Rossi AF, Courtney M, Gelb BD.
    J Heart Lung Transplant; 1998 Dec 20; 17(12):1195-200. PubMed ID: 9883760
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
    Casanovas T, Argudo A, Peña-Cala MC.
    Transplant Proc; 2011 Dec 20; 43(6):2233-6. PubMed ID: 21839242
    [Abstract] [Full Text] [Related]

  • 17. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
    Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G.
    Liver Transpl; 2001 May 20; 7(5):401-8. PubMed ID: 11349259
    [Abstract] [Full Text] [Related]

  • 18. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors.
    San Segundo D, Fábrega E, López-Hoyos M, Pons F.
    Transplant Proc; 2007 Sep 20; 39(7):2290-2. PubMed ID: 17889166
    [Abstract] [Full Text] [Related]

  • 19. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 20; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 20. Immunological advantages of everolimus versus cyclosporin A in liver-transplanted recipients, as revealed by polychromatic flow cytometry.
    Roat E, De Biasi S, Bertoncelli L, Rompianesi G, Nasi M, Gibellini L, Pinti M, Del Giovane C, Zanella A, Di Benedetto F, Gerunda GE, Cossarizza A.
    Cytometry A; 2012 Apr 20; 81(4):303-11. PubMed ID: 22311717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.